Radiation therapy for liver cancer that progresses after first immunotherapy
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding targeted radiation to liver cancer patients who have limited progression after initial immunotherapy can help control the disease. It is for people with hepatocellular carcinoma (HCC) whose cancer has started to grow in just a few spots after their first PD-1 treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed liver cancer diagnosis (by biopsy or imaging).
- Your cancer must have started to grow in 5 or fewer spots and in 3 or fewer organs after your first immunotherapy (PD-1 blocker).
- You should have had stable disease for at least 3 months while on that immunotherapy.
- Your overall health must be good enough for daily activities (ECOG 0 or 1).
- You cannot have had radiation therapy before for your liver cancer.
- You must be between 18 and 75 years old and willing to use contraception if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of liver-directed radiation therapy, an immunotherapy drug (which helps your immune system fight cancer), and a drug that blocks blood vessel growth to the tumor. It is for people with advanced liver cancer that cannot be treated with surgery.
This trial tests a combination of targeted radiation (photon radiotherapy) with two immunotherapy drugs (tremelimumab and durvalumab) for people with intermediate or advanced liver cancer that can't be surgically removed. The goal is to see if this combination can shrink tumors and improve outcomes.
This trial tests whether giving radiation to a few growing cancer spots while continuing your current treatment works better than switching to a new treatment right away. It's for people whose advanced liver cancer has only barely started to progress on their first therapy.
This trial tests a combination of radiation therapy, an immunotherapy drug (tislelizumab), and a targeted therapy drug (anlotinib) for people with liver cancer that has spread into the main blood vessel of the liver (portal vein). The goal is to see if this combination can shrink or control the cancer and improve outcomes.
This study tests a new combination for liver cancer that has not responded to one earlier treatment. It uses a focused type of radiation (SBRT) plus an immunotherapy drug called QL1706 (a medicine that helps your immune system attack cancer). The goal is to see if this combination can control the cancer better.
This study looks at whether adding radiation therapy to a combination of targeted therapy and immunotherapy helps people with advanced liver cancer live longer and feel better. It reviews records from patients treated at Zhongshan Hospital to compare outcomes with and without radiation.
Hear when a new Radiotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.